Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy
-
Published:2024-05
Issue:
Volume:133
Page:112014
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Wang ZhenhaoORCID,
Xu HaoORCID,
Mei Yu,
Xiao Min,
Cao Yang,
Huang LiangORCID,
Yang Zhuming,
Zhang Yicheng,
Han Zhiqiang,
Zheng Miao,
Hong ZhenyaORCID
Reference46 articles.
1. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study;Schuster;Lancet Oncol.,2021
2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial;Locke;Lancet Oncol.,2019
3. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;Abramson;Lancet,2020
4. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med.,2019
5. Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL);Abramson;Blood,2021